2379805-59-9
Chemical Structure
Unasnemab
Synonym(s): MT-3921; rH116A3
- CAS No.: 2379805-59-9
- Formula:N/A
- Molecular Weight:(144.88 kDa)
IUPAC Name: 2-(3-aminotetrahydrofuran-3-yl)ethan-1-ol
SMILES: [Unasnemab]
Biological Activity: Unasnemab (MT-3921) is a humanised IgG1 monoclonal antibody that binds to repulsive guidance molecule A (RGMa). Unasnemab improves locomotor function and promotes neuroregeneration. Unasnemab exerts ameliorative effects on hippocampal neurogenesis impairment and cognitive decline in db/db mice, Streptozotocin (STZ) (HY-13753)-induced type 1 diabetic and bilateral common carotid artery stenosis (BCAS)-induced mice. Unasnemab can be used for the research of spinal cord injury, diabetes-induced neurological impairments[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Unasnemab | 99.00% | Unasnemab (MT-3921) is a humanised IgG1 monoclonal antibody that binds to repulsive guidance molecule A (RGMa). Unasnemab improves locomotor function and promotes neuroregeneration. Unasnemab exerts ameliorative effects on hippocampal neurogenesis impairment and cognitive decline in db/db mice, Streptozotocin (STZ) (HY-13753)-induced type 1 diabetic and bilateral common carotid artery stenosis (BCAS)-induced mice. Unasnemab can be used for the research of spinal cord injury, diabetes-induced neurological impairments. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Araya N, et al. Virus-induced RGMa expression drives neurodegeneration in HTLV-1-associated myelopathy. JCI Insight. 2025 Apr 24;10(11):e184530. [Content Brief]
- [2]. Uno H, et al. Inhibition of repulsive guidance molecule A ameliorates diabetes-induced cognitive decline and hippocampal neurogenesis impairment in mice. Commun Biol. 2025 Feb 19;8(1):263. [Content Brief]
- [3]. Yamamoto M, et al. Anti-RGMa neutralizing antibody ameliorates vascular cognitive impairment in mice. Neurotherapeutics. 2025 Mar;22(2):e00500. [Content Brief]
Keywords
